Login to Your Account



Positive 'Restless Legs' Data Send XenoPort Shares Soaring

By Jennifer Boggs


Thursday, April 26, 2007
Shares of XenoPort Inc. leaped 44 percent on news that its gabapentin prodrug, XP13512, met its endpoints in the first of three Phase III studies in restless legs syndrome (RLS). (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription